You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Availability of nano-pharmaceutical drugs in Palestinian hospitals

From: A cross-sectional study of the availability and pharmacist’s knowledge of nano-pharmaceutical drugs in Palestinian hospitals

No. Nano-drug Total Government Private NGOs P-value
N = 56 (%) N = 29 (%) N = 17 (%) N = 10 (%)
1 Ambisome® 17 (30.4) 8 (14.3) 6 (10.7) 3 (5.4) 0.860
2 Rapamune® 5 (8.9) 3 (5.4) 0 (0.0) 2 (3.6) 0.197
3 Ritalin La® 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) >  0.999
4 Emend® 3 (5.4) 0 (0.0) 0 (0.0) 3 (5.4) 0.001
5 Swiss Relief® 22 (39.3) 1 (1.8) 14 (25.0) 7 (12.5) <  0.001
6 Invega® 1 (1.8) 0 (0.0) 1 (1.8) 0 (0.0) 0.311
7 Doxil® 2 (3.6) 2 (3.6) 0 (0.0) 0 (0.0) 0.381
8 Epaxal® 4 (7.1) 1 (1.8) 1 (1.8) 2 (3.6) 0.209
9 Mepact® 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) >  0.999
10 Mircera® 1 (1.8%) 1 (1.8) 0 (0.0) 0 (0.0) 0.623
11 Pegasys® 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) >  0.999
12 Somavert® 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) >  0.999
  1. P-value > 0.05 is insignificant value